Eli Lilly & Co: Weekly obesity/T2D volume tracker; TRx w/w: Zepbound -2.6%, Mounjaro -3.1%; 21.6k TRx for Foundayo with +8.9% w/w

Research evidence excerpt

Eli Lilly & Co: Weekly obesity/T2D volume tracker; TRx w/w: Zepbound -2.6%, Mounjaro -3.1%; 21.6k TRx for Foundayo with +8.9% w/w

Barclays | Eli Lilly & Co

• Foundayo IQVIA Capture Rate: We’ve updated our Lilly Foundayo model and attempted to

estimate IQVIA data capture rate with the variables given to us by LLY in 1Q26 earnings on

April 30th in addition to the Weekly IQVIA data and Daily IQVIA data that’s been reported thus

far (see chart below, we estimate capture rate to be ~mid 60s-80s%).

Eli Lilly's mgmt noted that >20K patients already started Foundayo and >1K patients were

added daily. More than 12 telehealth platforms currently offer Foundayo with ~35% of launch

volume, and management also noted ~45% of Foundayo volume currently coming from Lilly

Direct. Full DTC television advertising is planned for 3Q26 after baseline prescriber familiarity

is established.

FIGURE 1. IQVIA Daily + Weekly data + LLY provided metrics on Foundayo early launch

Full Launch Date Day 24 Day 26 Day 33 Day 40 Day 47 Day 54 Day 61 Day 62 Day 63 Day 64 Day 65 Day 66 Day 67 Day 68 Day 69 Day 70 Day 71 Day 72

Retail Daily Data Date Day 17 Day 19 Day 26 Day 33 Day 40 Day 47 Day 54 Day 55 Day 56 Day 57 Day 58 Day 59 Day 60 Day 61 Day 62 Day 63 Day 64 Day 65

Week Wed Fri Fri Fri Fri Fri Fri Sat Sun Mon Tue Wed Thu Fri Sat Sun Mon Tue

Date 4/29 5/1 5/8 5/15 5/22 5/29 6/5 6/6 6/7 6/8 6/9 6/10 6/11 6/12 6/13 6/14 6/15 6/16

Weekly TRx (sum of Daily TRx) 1,369 1,612 1,944 2,502 2,436 3,233 3,712

Daily TRx (as per IQVIA) 243 284 317 439 550 568 592 386 221 472 569 694 661 709 362 256 603 652

Cumulative Patients (from Daily TRx) 2,197 2,727 4,339 6,283 8,785 11,221 14,454 14,840 15,061 15,533 16,102 16,796 17,457 18,166 18,528 18,784 19,387 20,039

Day share of weekly TRx 17.8% 20.7% 20%